Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cisplatin + docetaxel followed by short-course radiotherapy and consolidation cisplatin + docetaxel in inoperable stage III non-small cell lung cancer
2008-006525-14Phase 2Active
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
- Start
- Dec 2008
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cisplatin and docetaxel in non-small cell lung cancer (NSCLC), sponsored by Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori". Primary endpoint: Objective tumor response rate. Started Dec 2008; status: active.
02
Drugs
cisplatindocetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2008-006525-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006525-14.